MarketPeel
Insider Trading Intelligence
Pricing
…
JT

James N. Topper

PHAT
DIRECTOR · PHATHOM PHARMACEUTICALS, INC. · CIK 0001341382
FILING MIX · LIFETIME73%/27%
BUYS
47
SELLS
17
TOTAL VALUE
$51.38M
COMPANIES
7
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
18,999,971
AVG SELL PX
—
TRADE KIND
SHOWING 64 / 64
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
20 backtested trades · 8 horizons · 19 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by James N. Topper, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d20+55.00%+6.60%+1.02%+5.58%+0.85%—
14d20+70.00%+7.93%+0.97%+6.96%+9.66%—
30d20+70.00%+63.29%+1.56%+61.73%+19.22%—
60d20+75.00%+72.51%+3.32%+69.19%+46.22%—
90d20+80.00%+82.16%+6.31%+75.85%+40.34%—
180d20+90.00%+128.81%+11.69%+117.12%+70.82%—
1y20(4 pending)+87.50%+138.06%+23.66%+114.39%+50.14%—
2y20(15 pending)+40.00%+129.16%+33.26%+95.91%-34.87%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
PHAT · 66,718 shares · as of May 19, 2026
01,456,8542,913,7084,370,5615,827,415202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 47 buys / 17 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
PHAT
PHATHOM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
24,122——66,718May 19, 2026May 21, 2026 ↗View →
MBX
MBX BIOSCIENCES, INC.
PURCHASE
666,666$18.00$12.00M5,219,440Sep 26, 2025Sep 30, 2025 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
PURCHASE
660$23.70$15.6K3,028,524Sep 15, 2025Sep 17, 2025 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
PURCHASE
1,260$24.99$31.5K3,027,864Sep 8, 2025Sep 10, 2025 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
PURCHASE
471$23.98$11.3K3,026,604Aug 11, 2025Aug 13, 2025 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
PURCHASE
1,260$18.26$23.0K3,026,133Jun 25, 2025Jun 26, 2025 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
PURCHASE
2,520$18.43$46.5K3,024,873Jun 24, 2025Jun 26, 2025 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
PURCHASE
8,584$19.50$167.4K3,022,153Jun 16, 2025Jun 18, 2025 ↗View →
PHAT
PHATHOM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
17,500——17,500Jun 3, 2025Jun 5, 2025 ↗View →
PHAT
PHATHOM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
10,500——42,596Jun 3, 2025Jun 5, 2025 ↗View →
PHAT
PHATHOM PHARMACEUTICALS, INC.
PURCHASE
3,780$3.86$14.6K59,403May 21, 2025May 23, 2025 ↗View →
PHAT
PHATHOM PHARMACEUTICALS, INC.
PURCHASE
6,300$3.32$20.9K55,623May 14, 2025May 15, 2025 ↗View →
PHAT
PHATHOM PHARMACEUTICALS, INC.
PURCHASE
1,120$3.16$3.5K49,323May 13, 2025May 15, 2025 ↗View →
PHAT
PHATHOM PHARMACEUTICALS, INC.
PURCHASE
12,601$3.04$38.3K48,203May 12, 2025May 13, 2025 ↗View →
PHAT
PHATHOM PHARMACEUTICALS, INC.
PURCHASE
33,376$3.19$106.6K33,376May 9, 2025May 13, 2025 ↗View →
PHAT
PHATHOM PHARMACEUTICALS, INC.
PURCHASE
2,226$3.62$8.1K35,602May 9, 2025May 13, 2025 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
PURCHASE
1,135$22.49$25.5K3,013,569Mar 26, 2025Mar 28, 2025 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
PURCHASE
4,005$21.02$84.2K3,012,434Mar 4, 2025Mar 6, 2025 ↗View →
MBX
MBX BIOSCIENCES, INC.
PURCHASE
625,000$16.00$10.00M4,552,774Sep 16, 2024Sep 17, 2024 ↗View →
MBX
MBX BIOSCIENCES, INC.
SALE
18,922,852——0Sep 16, 2024Sep 17, 2024 ↗View →
MBX
MBX BIOSCIENCES, INC.
PURCHASE
3,927,774——3,927,774Sep 16, 2024Sep 17, 2024 ↗View →
MBX
MBX BIOSCIENCES, INC.
SALE
28,297,265——0Sep 16, 2024Sep 17, 2024 ↗View →
PHAT
PHATHOM PHARMACEUTICALS, INC.
SALEGRANT
Stock grant
17,500——17,500May 23, 2024May 24, 2024 ↗View →
PHAT
PHATHOM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
10,500——32,096May 23, 2024May 24, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
PURCHASE
8,429$21.50$181.2K3,008,429Mar 26, 2024Mar 28, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
80,000$2.50$200.0K8,764,232Oct 24, 2023Oct 26, 2023 ↗View →
PHAT
PHATHOM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
15,000——15,000May 25, 2023May 30, 2023 ↗View →
PHAT
PHATHOM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
9,000——21,596May 25, 2023May 30, 2023 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
10,600——10,600Jan 6, 2023Jan 10, 2023 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
3,900——3,900Jan 6, 2023Jan 10, 2023 ↗View →
PHAT
PHATHOM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
20,000——20,000Sep 22, 2022Sep 26, 2022 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
250,000$20.00$5.00M8,684,232Aug 5, 2022Aug 9, 2022 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
9,200——9,200Feb 10, 2022Feb 14, 2022 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
2,108,558——8,434,232May 10, 2021May 12, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
96,574——0May 10, 2021May 12, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
96,574——96,574May 10, 2021May 12, 2021 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
11,000——11,000Feb 10, 2021Feb 12, 2021 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASE
26,354——80,812Nov 16, 2020Nov 18, 2020 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
344,860——700,171Nov 16, 2020Nov 18, 2020 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
973,612——0Nov 16, 2020Nov 18, 2020 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
98,275——199,529Nov 16, 2020Nov 18, 2020 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASE
22,604——54,458Nov 16, 2020Nov 18, 2020 ↗View →
TARS
TARSUS PHARMACEUTICALS, INC.
PURCHASE
214,281——1,604,657Oct 20, 2020Oct 20, 2020 ↗View →
TARS
TARSUS PHARMACEUTICALS, INC.
SALE
214,281——0Oct 20, 2020Oct 20, 2020 ↗View →
TARS
TARSUS PHARMACEUTICALS, INC.
PURCHASE
1,390,376——1,390,376Oct 20, 2020Oct 20, 2020 ↗View →
TARS
TARSUS PHARMACEUTICALS, INC.
SALE
1,390,376——0Oct 20, 2020Oct 20, 2020 ↗View →
TARS
TARSUS PHARMACEUTICALS, INC.
PURCHASE
312,500$16.00$5.00M1,917,157Oct 20, 2020Oct 20, 2020 ↗View →
PHAT
PHATHOM PHARMACEUTICALS, INC.
SALE
1,456,854——5,827,415Jun 12, 2020Jun 16, 2020 ↗View →
PHAT
PHATHOM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
10,000——10,000May 21, 2020May 22, 2020 ↗View →
PASG
PASSAGE BIO, INC.
PURCHASE
1,049,175——4,026,417Mar 3, 2020Mar 3, 2020 ↗View →
PASG
PASSAGE BIO, INC.
SALE
432,802——0Mar 3, 2020Mar 3, 2020 ↗View →
PASG
PASSAGE BIO, INC.
SALE
1,049,175——0Mar 3, 2020Mar 3, 2020 ↗View →
PASG
PASSAGE BIO, INC.
PURCHASE
550,000$18.00$9.90M5,009,219Mar 3, 2020Mar 3, 2020 ↗View →
PASG
PASSAGE BIO, INC.
PURCHASE
2,977,242——2,977,242Mar 3, 2020Mar 3, 2020 ↗View →
PASG
PASSAGE BIO, INC.
PURCHASE
432,802——4,459,219Mar 3, 2020Mar 3, 2020 ↗View →
PASG
PASSAGE BIO, INC.
SALE
2,977,242——0Mar 3, 2020Mar 3, 2020 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
11,000——11,000Feb 12, 2020Feb 13, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
6,360,272——0Feb 4, 2020Feb 6, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
6,360,272——6,869,304Feb 4, 2020Feb 6, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
2,099,019——0Feb 4, 2020Feb 6, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
1,074,467——10,042,790Feb 4, 2020Feb 6, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
1,074,467——0Feb 4, 2020Feb 6, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
500,000$17.00$8.50M10,542,790Feb 4, 2020Feb 6, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
2,099,019——8,968,323Feb 4, 2020Feb 6, 2020 ↗View →
Other insiders · PHAT
Loading peer insiders…
About this filer
CIK 0001341382
ROLE
Director
PRIMARY
PHAT
COMPANIES
7
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001341382DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback